Type 1 diabetes screening in pediatric primary care
What this study tests
Northwestern observational implementation study integrating islet-autoantibody screening into routine pediatric well-child visits. Clinics receive education, ordering reminders, and implementation facilitation; clinical screening still occurs at clinician discretion, while the study measures adoption and parent and clinician experience.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-07-20.
Most recent recorded citation date: 2026-07-20. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Children aged 1 and older attending clinic-selected well-child visits; parents/caregivers and clinic staff also contribute surveys or interviews. See registry for full criteria. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. A 20 July 2026 amendment increased estimated enrollment from 3,500 to 9,500 and set estimated start to 20 July 2026, but the registry still listed NOT_YET_RECRUITING on 8 August. Primary and study completion are estimated for 19 October 2027.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Parent and clinician acceptability, feasibility, and appropriateness over 15 months
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]Type 1 Diabetes Screening · Trial registry · 2026-07-20 — NOT_YET_RECRUITING; estimated n=9,500; estimated start 20 July 2026 and completion 19 October 2027. The passed estimated start date does not prove that sites opened; the registry remains the status source.